A new fentanyl lozenge will be out soon for cancer patients
January 1999
A new fentanyl lozenge will be out soon for cancer patients. It's called Actiq...and will be promoted by Anesta and Abbott.
Actiq is for "breakthrough" pain in cancer patients who are already on chronic opioids. Breakthrough pain is hard to treat because of its sudden onset and severity.
Actiq works fast...some of the drug is absorbed in the mouth. It starts working within 15 minutes and lasts for several hours.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote